ESC Congress 2024 — TEER non-inferior to mitral valve surgery with regard to death, HF rehospitalisation, stroke, reintervention of LVAD at one year.

Dr Volker Rudolph (Heart and Diabetes Center NRW, DE) and Prof Stephan Baldus (University Hospital of Köln, DE) joins us in London to discuss the MATTERHORN trial (NCT02371512; University Hospital of Köln).

This multicenter, randomized controlled trial evaluated mitral valve reconstruction strategies for patients with advanced functional or ischemic mitral regurgitation. A total of 210 participants with clinically significant, predominantly functional mitral regurgitation (MR), reduced left ventricular ejection fraction (LVEF ≥ 20%), and high surgical risk were enrolled. These patients experienced persistent heart failure symptoms despite optimal medical therapy. Participants were randomly assigned to either MitraClip therapy or surgical mitral valve repair. The primary outcome was a composite endpoint of death, heart failure rehospitalization, reintervention (repeat surgery or interventional procedure), device implantation, or stroke occurring within twelve months post-intervention.

Findings showed that TEER was non-inferior to mitral valve surgery, with a favourable safety profile of TEER as compared to surgery. 

Interview Questions: 

1. What is the background to this trial?
2. What was the study design, eligibility criteria and outcome measures?
3. What are the baseline characteristics of the patients?
4. What are the key findings?
5. Are there specific patient subgroups that benefit more from one treatment over the other?
6. What are the take-home messages for practice?
7. What are the next steps?

Recorded on-site at ESC Congress 2024, London.

Editors: Jordan Rance and Mirjam Boros.
Videographers: Mike Knight, Dan Brent, Oliver Miles, Tom Green, David-Ben-Harosh.

Support: This is an independent interview produced by Radcliffe Cardiology.